A simple assay for determination of levetiracetam in rat dried blood spots by LC-MS/MS

Bioanalysis

Volumn 5, Issue 15, 2013, Pages 1843-1851

  Luo, Wenxia ^a   Kong, Sing Teang ^a   Yang, Shili ^a   Chan, Bernice Choi Wai ^a   Ho, Paul C ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ETIRACETAM; METHANOL;

ACCURACY; ANIMAL EXPERIMENT; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DRIED BLOOD SPOT TESTING; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG ISOLATION; DRUG MONITORING; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; QUANTITATIVE ANALYSIS; RAT; TANDEM MASS SPECTROMETRY; VALIDATION STUDY;

ANIMALS; ANTICONVULSANTS; CALIBRATION; CHROMATOGRAPHY, LIQUID; DRIED BLOOD SPOT TESTING; LIMIT OF DETECTION; MALE; PIRACETAM; RATS; RATS, SPRAGUE-DAWLEY; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY;

EID: 84881290076     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.13.143     Document Type: Article

References (40)

1. Shorvon S. Pyrrolidone derivatives. Lancet 358(9296), 1885-1892 (2001).
2. Lynch BA, Lambeng N, Nocka K et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc. Natl Acad. Sci. USA 101(26), 9861-9866 (2004).
3. Gillard M, Chatelain P, Fuks B. Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein. Eur. J. Pharmacol. 536(1-2), 102-108 (2006).
4. Patsalos PN. Pharmacokinetic profile of levetiracetam: Toward ideal characteristics. Pharmacol. Therap. 85(2), 77-85 (2000).
5. Mendu DR, Soldin SJ. Simultaneous determination of levetiracetam and its acid metabolite (ucb L057) in serum/plasma by liquid chromatography tandem mass spectrometry. Clin. Biochem. 43(4-5), 485-489 (2010).
6. Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin. Pharmacokinetics 43(11), 707-724 (2004).
7. Folland C, Moriarty GL. Clinical experience of levetiracetam (LEV) in refractory adult epilepsy patients [abstract]. Epilepsia 43(Suppl. S7), 192 (2002).
8. Mushtaq R, Wannamaker BB. Levetiracetam blood levels have utility in clinical management of epilepsy [abstract]. Epilepsia 43(Suppl. S7), 107 (2002).
9. Lindholm D. Levetiracetam levels correlating with successful treatment of epilepsy, headaches, cognitive effects, and adverse reactions in pediatric age group [abstract]. Epilepsia 43(Suppl. S7), 60 (2002).
10. Radtke RA. Pharmacokinetics of levetiracetam. Epilepsia, 42(Suppl. S4), 24-27 (2001).
11. Doheny HC, Ratnaraj N, Whittington MA, Jefferys JGR, Patsalos PN. Blood and cerebrospinal fluid pharmacokinetics of the novel anticonvulsant levetiracetam (ucb L059) in the rat. Epilepsy Res. 34(2-3), 161-168 (1999).
12. Blonk MI, van der Nagel BC, Smit LS, Mathot RA. Quantification of levetiracetam in plasma of neonates by ultra performance liquid chromatography-tandem mass spectrometry. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 878(7-8), 675-681 (2010).
13. Matar KM. Quantification of levetiracetam in human plasma by liquid chromatography- tandem mass spectrometry: Application to therapeutic drug monitoring. J. Pharm. Biomed. Anal. 48(3), 822-828 (2008).
14. Perucca E, Bialer M. The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. Clin. Pharmacokinet. 31(1), 29-46 (1996).
15. Pellock JM, Glauser TA, Bebin EM et al. Pharmacokinetic study of levetiracetam in children. Epilepsia 42(12), 1574-1579 (2001).
16. Garcia Boy R, Henseler J, Mattern R, Skopp G. Determination of morphine and 6-acetylmorphine in blood with use of dried blood spots. Ther. Drug Monit. 30(6), 733-739 (2008).
17. la Marca G, Malvagia S, Filippi L, Luceri F, Moneti G, Guerrini R. A new rapid micromethod for the assay of phenobarbital from dried blood spots by LC-tandem mass spectrometry. Epilepsia 50(12), 2658-2662 (2009).
18. Rowland M, Emmons GT. Use of dried blood spots in drug development: Pharmacokinetic considerations. AAPS J. 12(3), 290-293 (2010).
19. Spooner N, Lad R, Barfield M. Dried blood spots as a sample collection technique for the determination of pharmacokinetics in clinical studies: Considerations for the validation of a quantitative bioanalytical method. Analyt. Chem. 81(4), 1557-1563 (2009).
20. Mei JV, Alexander JR, Adam BW, Hannon WH. Use of filter paper for the collection and analysis of human whole blood specimens. J. Nutr. 131(5), 1631S-1636S (2001).
21. Vermeij TAC, Edelbroek PM. High-performance liquid chromatographic and megabore gas-liquid chromatographic determination of levetiracetam (ucb LO59) in human serum after solid-phase extraction. J. Chromatogr. B. Biomed. Sci. Appl. 662(1), 134-139 (1994).
22. Isoherranen N, Roeder M, Soback S, Yagen B, Schurig V, Bialer M. Enantioselective analysis of levetiracetam and its enantiomer R-a-ethyl-2-oxo-pyrrolidine acetamide using gas chromatography and ion trap mass spectrometric detection. J. Chromatogr. B. Biomed. Sci. Appl. 745(2), 325-332 (2000).
23. Ivanova M, Piunti A, Marziali E, Komarova N, Raggi MA, Kenndler E. Microemulsion electrokinetic chromatography applied for separation of levetiracetam from other antiepileptic drugs in polypharmacy. Electrophoresis 24(6), 992-998 (2003).
24. Ratnaraj N, Doheny HC, Patsalos PN. A micromethod for the determination of the new antiepileptic drug levetiracetam (ucb LO59) in serum or plasma by high performance liquid chromatography. Ther. Drug Monit. 18(2), 154-157 (1996).
25. Pucci V, Bugamelli F, Mandrioli R, Ferranti A, Kenndler E, Raggi MA. High-performance liquid chromatographic determination of Levetiracetam in human plasma: Comparison of different sample clean-up procedures. Biomed. Chromatogr. 18(1), 37-44 (2004).
26. Martens-Lobenhoffer J, Bode-Boger SM. Determination of levetiracetam in human plasma with minimal sample pretreatment. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 819(1), 197-200 (2005).
27. Juenke J, Brown PI, Urry FM, McMillin GA. Drug monitoring and toxicology: A procedure for the monitoring of levetiracetam and zonisamide by HPLC-UV. J. Analyt. Toxicol. 30(1), 27-30 (2006).
28. Shah NM, Hawwa AF, Millership JS, Collier PS, McElnay JC. A simple bioanalytical method for the quantification of antiepileptic drugs in dried blood spots. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 923-924, 65-73 (2013).
29. Jain DS, Subbaiah G, Sanyal M, Pal U, Shrivastav PS. Determination of levetiracetam in human plasma by liquid chromatography/ electrospray tandem mass spectrometry and its application to bioequivalence studies. Rapid Commun. Mass Spectrom. 20(17), 2539-2547 (2006).
30. Guo T, Oswald LM, Mendu DR, Soldin SJ. Determination of levetiracetam in human plasma/serum/saliva by liquid chromatography-electrospray tandem mass spectrometry. Clin. Chim. Acta 375(1-2), 115-118 (2007).
31. Kim KB, Seo KA, Kim SE, Bae SK, Kim DH, Shin JG. Simple and accurate quantitative analysis of ten antiepileptic drugs in human plasma by liquid chromatography/tandem mass spectrometry. J. Pharm. Biomed. Anal. 56(4), 771-777 (2011).
32. National Advisory Committee for Laboratory Animal Research. Guidelines on the Care and Use of Animals for Scientific Purposes. (Singapore) (2004).
33. US FDA. Guidance of Industry Bioanalytical Method Validation. US FDA, MD, USA (2001).
34. Ramakers BP, Pickkers P, Deussen A et al. Measurement of the endogenous adenosine concentration in humans in vivo: Methodological considerations. Curr. Drug Metab. 9(8), 679-685 (2008).
35. Benedetti MS, Coupez R, Whomsley R, Nicolas JM, Collart P, Baltes E. Comparative pharmacokinetics and metabolism of levetiracetam, a new anti-epileptic agent, in mouse, rat, rabbit and dog. Xenobiotica 34(3), 281-300 (2004).
36. Li W, Tse FL. Dried blood spot sampling in combination with LC-MS/MS for quantitative analysis of small molecules. Biomed. Chromatogr. 24(1), 49-65 (2010).
37. Adam BW, Alexander JR, Smith SJ et al. Recoveries of phenylalanine from two sets of dried-blood-spot reference materials: Prediction from hematocrit, spot volume, and paper matrix. Clin. Chem. 46(1), 126-128 (2000).
38. Holub M, Tuschl K, Ratschmann R et al. Influence of hematocrit and localisation of punch in dried blood spots on levels of amino acids and acylcarnitines measured by tandem mass spectrometry. Clin. Chim. Acta 373(1-2), 27-31 (2006).
39. Eyles D, Anderson C, Ko P et al. A sensitive LC/MS/MS assay of 25OH vitamin D3 and 25OH vitamin D2 in dried blood spots. Clin. Chim. Acta 403(1-2), 145-151 (2009).
40. McClure FJ, Kornberg A. Blood hemoglobin and hematocrit results on rats ingesting sodium fluoride. J. Pharmacol. Exp. Therap. 89(1), 77-80 (1947).